Cisplatin as second-line chemotherapy for docetaxel-refractory prostate cancer

An Italian research team has published data from a small Phase II clinical trial suggesting that cisplatin + prednisone has activity in the treatment of men with castration-resistant prostate cancer (CRPC) who have already progressed after treatment with a docetaxel-based chemotherapy regimen. … READ MORE …

A possible chemotherapy for small cell carcinoma of the prostate?

Small cell carcinoma of the prostate or SCCP is a rare, aggressive, and treatment-refractory form of prostate cancer. No good form of treatment is yet known for this disease, and median survival from initial diagnosis is less than 2 years. … READ MORE …

More weekend news: Sunday, November 30, 2008

There are a bunch of new but distinctly technical reports today that will probably be of limited interest to the majority of readers, but in the interests of knowledge please feel free to … READ MORE …